James E. Flynn - 31 Dec 2024 SCHEDULE 13G/A Report for Prelude Therapeutics Incorporated Common Stock (PRLD)

Filing Manager
James E. Flynn
Reporting Manager
Deerfield Mgmt, L.P.
Security
Prelude Therapeutics Incorporated Common Stock
Symbol
PRLD
Disclosed Ownership
0 shares
Ownership
0%
Form type
SCHEDULE 13G/A
Filing time
13 Feb 2025, 08:58:41 UTC
Date of event
31 Dec 2024
SEC
View on sec.gov

Quoteable Key Fact

"James E. Flynn disclosed 0% ownership in Prelude Therapeutics Incorporated Common Stock (PRLD) on 31 Dec 2024."

Quick Takeaways

  • James E. Flynn filed SCHEDULE 13G/A for Prelude Therapeutics Incorporated Common Stock (PRLD).
  • Disclosed ownership: 0%.
  • Date of event: 31 Dec 2024.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 13 Feb 2025, 08:58.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (4)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Deerfield Mgmt, L.P. 0% 0 0 0 /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact
Deerfield Management Company, L.P. 0% 0 0 0 /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact
Deerfield Partners, L.P. 0% 0 0 0 /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact
James E. Flynn 0% 0 0 0 /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact